Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Update July 2023

Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Update July 2023. Oncology Fact Sheet Nr. 118.

[thumbnail of Fact Sheet Nr.118_2nd Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
849kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 700-770 Liver. Billary tract
Language:	English
Series Name:	Oncology Fact Sheet Nr. 118
Deposited on:	01 Feb 2023 15:39
Last Modified:	26 Jul 2023 10:10

Repository Staff Only: item control page